These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 36795195

  • 1. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
    Nappo F, Fornaro L, Pompella L, Catanese S, Lavacchi D, Spallanzani A, Cappetta A, Puzzoni M, Murgioni S, Barsotti G, Tirino G, Pellino A, Vivaldi C, Strippoli A, Aprile G, Di Donato S, Mazza E, Prisciandaro M, Antonuzzo L, Zagonel V, Cascinu S, De Vita F, Lonardi S.
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
    [Abstract] [Full Text] [Related]

  • 2. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
    Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, Morano F, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F.
    Eur J Cancer; 2024 May; 203():114043. PubMed ID: 38598921
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
    Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfeld C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M.
    Int J Cancer; 2019 Apr 01; 144(7):1697-1703. PubMed ID: 30499151
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U, Parente P, Pepe F, De Luca C, Pisapia P, Sgariglia R, Nacchio M, Gragnano G, Russo G, Conticelli F, Bellevicine C, Vigliar E, Iaccarino A, Covelli C, Balistreri M, Clemente C, Perrone G, Danza A, Scaramuzzi F, Fassan M, Troncone G, Graziano P.
    Cells; 2021 Jul 24; 10(8):. PubMed ID: 34440647
    [Abstract] [Full Text] [Related]

  • 5. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY, Lin TA, Huang SC, Hsu JT, Yeh CN, Chen TC, Chiu CT, Chen JS, Yeh TS.
    Oncologist; 2020 Jul 24; 25(7):e1021-e1030. PubMed ID: 32058649
    [Abstract] [Full Text] [Related]

  • 6. Results of the observational prospective RealFLOT study.
    Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, Antonuzzo L.
    BMC Cancer; 2021 Oct 08; 21(1):1086. PubMed ID: 34625033
    [Abstract] [Full Text] [Related]

  • 7. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC, Jin Y, Lei XF, Wang ZX, Zhang DS, Wang FH, Li YH, Xu RH, Wang F.
    J Cancer; 2022 Oct 08; 13(9):2912-2921. PubMed ID: 35912009
    [Abstract] [Full Text] [Related]

  • 8. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z, Wang Y, Ying X, Zhang L, Gao X, Jia Y, Zhang L, Wu A, Su X, Ji J.
    J Surg Oncol; 2021 Dec 08; 124(8):1356-1364. PubMed ID: 34515995
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
    Nie RC, Chen GM, Yuan SQ, Kim JW, Zhou J, Nie M, Feng CY, Chen YB, Chen S, Zhou ZW, Wang Y, Li YF.
    Ann Surg Oncol; 2022 Apr 08; 29(4):2324-2331. PubMed ID: 34796431
    [Abstract] [Full Text] [Related]

  • 10. The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis.
    Guan WL, Ma Y, Cui YH, Liu TS, Zhang YQ, Zhou ZW, Xu JY, Yang LQ, Li JY, Sun YT, Xu RH, Wang FH, Qiu MZ.
    Front Oncol; 2021 Apr 08; 11():712760. PubMed ID: 34900669
    [Abstract] [Full Text] [Related]

  • 11. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.
    Ooki A, Osumi H, Yoshino K, Yamaguchi K.
    Gastric Cancer; 2024 Sep 08; 27(5):907-931. PubMed ID: 38922524
    [Abstract] [Full Text] [Related]

  • 12. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
    Jin Z, Sanhueza CT, Johnson B, Nagorney DM, Larson DW, Mara KC, Harmsen WC, Smyrk TC, Grothey A, Hubbard JM.
    Oncologist; 2018 Sep 08; 23(9):1083-1091. PubMed ID: 29674439
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M.
    J Clin Oncol; 2023 Jan 10; 41(2):255-265. PubMed ID: 35969830
    [Abstract] [Full Text] [Related]

  • 14. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A.
    Lancet Oncol; 2016 Dec 10; 17(12):1697-1708. PubMed ID: 27776843
    [Abstract] [Full Text] [Related]

  • 15. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
    Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T.
    Bull Cancer; 2020 Apr 10; 107(4):438-446. PubMed ID: 32057467
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
    Erol C, Sakin A, Başoğlu T, Özden E, Çabuk D, Doğan M, Öksüzoğlu B, Yıldırım HÇ, Öner İ, Eryılmaz MK, Dülgar Ö, Aydın D, Doğan N, Özen M, Hacıbekiroğlu İ, Özdemir N, Gürler F, Paksoy N, Karabulut S, Aksoy A, Hızal M, Kahraman S, Şen E, Paydaş S, Çılbır E, Fırat F, Akdeniz N, Özçelik M, Oyman A, Baytemür NK, Acar R, Almuradova E, Karabulut B, Şakalar T, Arak H, Değerli E, Türker S, Alan Ö, Er Ö, Taşçı EŞ, Demir N, Çavdar E, Turhal S, Dede DŞ, Akıncı MB, Yalçın B, Yumuk F, Yalçın Ş, Şendur MAN.
    Turk J Med Sci; 2022 Aug 10; 52(4):1022-1032. PubMed ID: 36326360
    [Abstract] [Full Text] [Related]

  • 17. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
    van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM.
    Cancer Treat Rev; 2020 Jun 10; 86():102024. PubMed ID: 32388292
    [Abstract] [Full Text] [Related]

  • 18. Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
    Quaas A, Biesma HD, Wagner AD, Verheij M, van Berge Henegouwen MI, Schoemig-Markiefka B, Pamuk A, Zander T, Siemanowski J, Sikorska K, Egthuijsen JMP, Meershoek-Klein Kranenbarg EM, van de Velde CJH, Buettner R, Alakus H, Cats A, Ylstra B, van Laarhoven HWM, van Grieken NCT.
    Eur J Cancer; 2022 Sep 10; 173():95-104. PubMed ID: 35863110
    [Abstract] [Full Text] [Related]

  • 19. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.
    J Natl Cancer Inst; 2011 Jun 08; 103(11):863-75. PubMed ID: 21597022
    [Abstract] [Full Text] [Related]

  • 20. Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
    Fornaro L, Lonardi S, Catanese S, Nappo F, Pietrantonio F, Pellino A, Angerilli V, Signorini F, Salani F, Murgioni S, Neculaescu IA, Bruno R, Vivaldi C, Ricagno G, Masi G, Bergamo F, Ugolini C, Fassan M.
    Gastric Cancer; 2023 Nov 08; 26(6):958-968. PubMed ID: 37382783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.